Literature DB >> 28212963

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force.

John H Powers1, Donald L Patrick2, Marc K Walton3, Patrick Marquis4, Stefan Cano5, Jeremy Hobart6, Maria Isaac7, Spiros Vamvakas8, Ashley Slagle9, Elizabeth Molsen10, Laurie B Burke11.   

Abstract

A clinician-reported outcome (ClinRO) assessment is a type of clinical outcome assessment (COA). ClinRO assessments, like all COAs (patient-reported, observer-reported, or performance outcome assessments), are used to 1) measure patients' health status and 2) define end points that can be interpreted as treatment benefits of medical interventions on how patients feel, function, or survive in clinical trials. Like other COAs, ClinRO assessments can be influenced by human choices, judgment, or motivation. A ClinRO assessment is conducted and reported by a trained health care professional and requires specialized professional training to evaluate the patient's health status. This is the second of two reports by the ISPOR Clinical Outcomes Assessment-Emerging Good Practices for Outcomes Research Task Force. The first report provided an overview of COAs including definitions important for an understanding of COA measurement practices. This report focuses specifically on issues related to ClinRO assessments. In this report, we define three types of ClinRO assessments (readings, ratings, and clinician global assessments) and describe emerging good measurement practices in their development and evaluation. The good measurement practices include 1) defining the context of use; 2) identifying the concept of interest measured; 3) defining the intended treatment benefit on how patients feel, function, or survive reflected by the ClinRO assessment and evaluating the relationship between that intended treatment benefit and the concept of interest; 4) documenting content validity; 5) evaluating other measurement properties once content validity is established (including intra- and inter-rater reliability); 6) defining study objectives and end point(s) objectives, and defining study end points and placing study end points within the hierarchy of end points; 7) establishing interpretability in trial results; and 8) evaluating operational considerations for the implementation of ClinRO assessments used as end points in clinical trials. Applying good measurement practices to ClinRO assessment development and evaluation will lead to more efficient and accurate measurement of treatment effects. This is important beyond regulatory approval in that it provides evidence for the uptake of new interventions into clinical practice and provides justification to payers for reimbursement on the basis of the clearly demonstrated added value of the new intervention.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical trials; clinician-reported outcomes; end points; outcome assessments

Mesh:

Year:  2017        PMID: 28212963      PMCID: PMC5379997          DOI: 10.1016/j.jval.2016.11.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  38 in total

1.  Assessing similarity between profiles.

Authors:  L J CRONBACH; G C GLESER
Journal:  Psychol Bull       Date:  1953-11       Impact factor: 17.737

2.  Observers' errors in taking medical histories.

Authors:  A L COCHRANE; P J CHAPMAN; P D OLDHAM
Journal:  Lancet       Date:  1951-05-05       Impact factor: 79.321

3.  Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study.

Authors:  Manfred Döpfner; Hans-Christoph Steinhausen; David Coghill; Søren Dalsgaard; Lynne Poole; Stephen J Ralston; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

4.  The effect of measuring error on the results of therapeutic trials in advanced cancer.

Authors:  C G Moertel; J A Hanley
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

Review 5.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Authors:  George H Talbot; John H Powers; Thomas R Fleming; Judith A Siuciak; John Bradley; Helen Boucher
Journal:  Clin Infect Dis       Date:  2012-06-28       Impact factor: 9.079

6.  Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.

Authors:  Leonard V Sacks; Hala H Shamsuddin; Yuliya I Yasinskaya; Khaled Bouri; Michael L Lanthier; Rachel E Sherman
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

7.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

8.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Authors:  E Rubinstein; S Cammarata; T Oliphant; R Wunderink
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

Review 9.  Symptom rating scales and outcome in schizophrenia.

Authors:  Ann M Mortimer
Journal:  Br J Psychiatry Suppl       Date:  2007-08

10.  Global rating of change scales: a review of strengths and weaknesses and considerations for design.

Authors:  Steven J Kamper; Christopher G Maher; Grant Mackay
Journal:  J Man Manip Ther       Date:  2009
View more
  31 in total

1.  Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Authors:  George H Talbot; John H Powers; Steven C Hoffmann
Journal:  Clin Infect Dis       Date:  2015-12-13       Impact factor: 9.079

2.  A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials.

Authors:  Melissa Raspa; Carla M Bann; Angela Gwaltney; Timothy A Benke; Cary Fu; Daniel G Glaze; Richard Haas; Peter Heydemann; Mary Jones; Walter E Kaufmann; David Lieberman; Eric Marsh; Sarika Peters; Robin Ryther; Shannon Standridge; Steven A Skinner; Alan K Percy; Jeffrey L Neul
Journal:  Am J Intellect Dev Disabil       Date:  2020-11-01

Review 3.  Digital Medicine: A Primer on Measurement.

Authors:  Andrea Coravos; Jennifer C Goldsack; Daniel R Karlin; Camille Nebeker; Eric Perakslis; Noah Zimmerman; M Kelley Erb
Journal:  Digit Biomark       Date:  2019-05-09

Review 4.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

Review 5.  Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.

Authors:  Joan Busner; Gahan Pandina; SilviaZaragoza Domingo; Anna-Karin Berger; Maria T Acosta; Nahome Fisseha; Joseph Horrigan; Jelena Ivkovic; William Jacobson; Dennis Revicki; Victoria Villalta-Gil
Journal:  Innov Clin Neurosci       Date:  2021 Oct-Dec

6.  Change in functioning outcomes as a predictor of the course of depression: a 12-month longitudinal study.

Authors:  Carlos G Forero; Elena Olariu; Pilar Álvarez; José-Ignacio Castro-Rodriguez; Maria Jesús Blasco; Gemma Vilagut; Víctor Pérez; Jordi Alonso
Journal:  Qual Life Res       Date:  2018-04-10       Impact factor: 4.147

7.  Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations.

Authors:  Nathaniel Katz; Robert H Dworkin; Richard North; Simon Thomson; Sam Eldabe; Salim M Hayek; Brian H Kopell; John Markman; Ali Rezai; Rod S Taylor; Dennis C Turk; Eric Buchser; Howard Fields; Gregory Fiore; McKenzie Ferguson; Jennifer Gewandter; Chris Hilker; Roshini Jain; Angela Leitner; John Loeser; Ewan McNicol; Turo Nurmikko; Jane Shipley; Rahul Singh; Andrea Trescot; Robert van Dongen; Lalit Venkatesan
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

Review 8.  First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.

Authors:  Laurent Servais; Eric Camino; Aude Clement; Craig M McDonald; Jacek Lukawy; Linda P Lowes; Damien Eggenspieler; Francesca Cerreta; Paul Strijbos
Journal:  Digit Biomark       Date:  2021-08-05

9.  Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Authors:  Suzanne Kafaja; Philip J Clements; Holly Wilhalme; Chi-Hong Tseng; Daniel E Furst; Grace Hyun Kim; Jonathan Goldin; Elizabeth R Volkmann; Michael D Roth; Donald P Tashkin; Dinesh Khanna
Journal:  Am J Respir Crit Care Med       Date:  2017-11-03       Impact factor: 30.528

Review 10.  The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force.

Authors:  Jessica K Roydhouse; Matthew L Cohen; Henrik R Eshoj; Nadia Corsini; Emre Yucel; Claudia Rutherford; Katarzyna Wac; Allan Berrocal; Alyssa Lanzi; Cindy Nowinski; Natasha Roberts; Angelos P Kassianos; Veronique Sebille; Madeleine T King; Rebecca Mercieca-Bebber
Journal:  Qual Life Res       Date:  2021-07-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.